Objective. Patients with chronic pain considered for steroid injections are not consistently screened for undiagnosed or poorly controlled diabetes mellitus (DM) prior to steroid administration despite the known impact of corticosteroids on glucose control. A quality improvement project was undertaken to identify the prevalence of at-risk patients prior to steroid exposure through the development and implementation of a screening questionnaire.
Introduction
Corticosteroid injections are common interventional procedures frequently utilized in the treatment of multiple chronic pain states. However, corticosteroid injections have been shown to cause elevation of glucose production and reduction of insulin sensitivity, leading to worsened glucose control [1, 2] . As a result, steroid injections expose patients with poorly controlled diabetes mellitus (DM) to significant risks. This becomes increasingly concerning as the proportion of the population with diabetes mellitus continues to grow. In 2014, the US Centers for Disease Control and Prevention estimated that 29.1 million people in the United States (9.3% of the population) have diabetes. Approximately 27.8% of those 29.1 million people are undiagnosed. Furthermore, an estimated 79 million people have prediabetes, a condition that puts them at increased risk for developing diabetes [1] .
The therapeutic efficacy of corticosteroid injections is not affected by the presence of DM. A retrospective cohort study by Ma and Shakir (2013) showed that the presence of type 2 DM does not impair the therapeutic efficacy of transforaminal-cervical epidural steroid injections (ESI) in the treatment of cervical radiculopathy [2] . Unfortunately, corticosteroid injections do put patients at increased risk of developing hyperglycemia, which may manifest as DM complications, secondary to an increase in insulin resistance. Ward et al. (2002) [3] showed that administration of a single caudal epidural injection containing 80 mg triamcinolone resulted in significant suppression of insulin sensitivity, as measured by euglycemic-hyperinsulinemic clamp technique (pre-epidural insulin sensitivity, kITT ¼ 3.6%/min; 24 h postepidural kITT ¼ 1.9%/min, P ¼ 0.001). This insulin resistance was temporary and returned to baseline within one week of ESI. Similarly, a prospective cohort study by Even et al. (2012) [4] found that glucose levels increase by a mean of 79% from baseline in patients following a single interlaminar ESI injection containing 40 mg of betamethasone and 1 mL of saline (N ¼ 30, baseline glucose level 160.18 47.46, post-ESI glucose level 286.13 6 111.11). Similar to Ward et al. [3] , Gonzales et al. showed effects on glucose metabolism. In this study, the glucose levels were elevated by an average of 106 mg/dl on the evening of a lumbosacral or caudal injection of betamethasone, and there were significant elevations in blood glucose levels for three days postinjection [5] .
An additional concern is that patients with preexisting diabetes have been found to experience a more significant increase in blood glucose levels following corticosteroid therapy compared with nondiabetics (absence of preexisting DM). Younes et al. (2007) [6] administered three injections of 5.625 mg cortivazol into either the epidural space (18 patients, 4 diabetics) or the shoulder joint (11 patients, 8 diabetics) in 29 patients at three-day intervals. The fasting and postprandial blood glucose (PBG) levels of these patients were then tracked at post-treatment visits on days 1, 7, and 21 following the third injection. Results showed a more marked increase and longer duration of elevated PBG in patients with preexisting diabetes (baseline of 169.36 6 59.45 mg/dl, 255.85 6 9.9 mg/dl at day 1, and 250.4 6 86.48 mg/dl at day 7) compared with patients without known DM (baseline 111.71 6 30.63 mg/dl, 129.72 6 54.05 mg/dl at day 1, no significant elevation at day 7).
With respect to different techniques and injection sites for the administration of glucocorticoid therapy, Moon et al. (2014) [7] found no significant difference in the magnitude of change in fasting blood glucose (FBG) or the duration of blood glucose elevation when comparing ESI with glenohumoral joint injections. However, studies have shown that the dose of corticosteroid administered does affect the magnitude of insulin resistance observed. Kim et al. (2013) [8] compared the effects of two varying doses of triamcinolone (40 mg vs 20 mg) on blood glucose level and pain control in patients with diabetes. FBG and PBG were checked on postprocedure days (PPD) 1 and 3. Statistically significant increases in FBG and PBG were found after ESI in both subgroups. However, FBG was elevated for a longer duration (PPD3 vs PPD1, respectively) and to a larger magnitude (FBG on PPD#1: 179 mg/dl vs 146 mg/dl, respectively) in the 40-mg dosing subgroup compared with the 20-mg subgroup. Interestingly, no difference in subjective pain score was found between the two groups during the two weeks postinjection. Therefore, with respect to glucose and pain control, the authors recommended 20 mg of triamcinolone over 40 mg in patients with diabetes [8] .
DM in patients seen at the pain management center may be undiagnosed, inadequately recorded in the electronic medical record, unreported by the patient, or unacknowledged by the pain management physician. This failure to identify patients with pre-DM or poorly controlled DM may lead to increased patient morbidity and mortality. A questionnaire including the American Diabetes Association screening questionnaire (ADAQ) and nine signs and symptoms of hyperglycemia was used to screen for patients presenting to a university comprehensive pain management center who had a diagnosis that could have included steroid administration as part of the treatment plan. The symptom checklist was included, after review of the literature and discussion with a diabetologist, to determine if it improved identification of potentially hyperglycemic patients. We sought to determine the prevalence of patients at risk of inadequate glucose control that could be worsened by a corticosteroid exposure in order to determine if routine screening should be implemented prior to interventional treatment involving corticosteroids.
Methods
A diabetes screening questionnaire was administered as part of an institutional review board (IRB)-approved quality improvement project. The pain diagnoses of consecutive patients presenting to the University of Virginia Pain Management Center over a two-month span were reviewed by a research coordinator. Those who, by virtue of their pain diagnosis, could be considered for a future steroid injection were asked to complete an anonymous and voluntary questionnaire. The primary pain diagnosis was also noted. We utilized chart review to identify the patient's DM status when available, including documented blood work (fasting blood glucose, hemoglobin A1C). Patients were also asked for their most recent fasting blood glucose level or hemoglobin A1C (Hgb A1C), if applicable.
ADA Validated Questionnaire and Study Questionnaire
All enrolled patients completed an ADAQ, which was adapted from and validated by Bang et al. (2009) [9] . The ADAQ consisted of seven questions regarding age, gender, BMI, history of gestational DM, history of hypertension, family history of DM, and physical activity. A single point was given for patients who were between age 40 and 49 years, two points were given for age 50 to 59 years, and three points were given for patients older than 60 years of age. A point was also given for patients who were male, had a history of gestational DM, had a diagnosis of hypertension, or were not physically active (determined subjectively by the patient).
Patients were also assigned between one and three points based on their weight, as determined by their BMI (one point for BMI between 25 and 29, two points for BMI between 30 and 39, and three points for BMI greater than 40). Per Bang et al. [9] , for the ADAQ, a score of five or greater was selected as a positive screen, indicating the patient to be at high risk for undiagnosed DM. This cutoff threshold was validated to identify 35% of the adult population as high risk for undiagnosed diabetes and yield a sensitivity of 79%.
Patients completed a study questionnaire (SQ), which consisted of the ADAQ and an additional symptom survey. The symptom survey consisted of nine symptombased questions that addressed common signs and symptoms prevalent in the diabetic (patients suffering with DM) population, including frequent urination, excessive thirst, excessive hunger, recent unusual weight change, excessive fatigue, blurring of vision, numbness in the extremities, and repeated skin, gum, or bladder infections. Each positive response received a score of 1, and a total survey score was calculated by summing the total number of positive symptoms. The SQ score was determined through summation of the symptom score with the ADAQ score. A SQ score of 8 or greater was deemed to be a positive screen, that is, high risk for undiagnosed or undertreated diabetes. This cutoff threshold was selected as it yielded a comparable sensitivity (85%), specificity (44%), positive predictive value (PPV) (28%), and negative predictive value (NPV) (92%) to the validated ADAQ (87%, 40%, 27%, 92%, respectively) ( Table 1 ).
Diabetes Mellitus Education
All patients who screened positive on either the ADAQ or the SQ received additional diabetes education. These patients were encouraged to speak to their primary care physician about their risk of DM. Patients were given an opportunity to have their questions answered and received additional resources to facilitate further independent education.
Data Analysis
Patient demographics, including gender, age, family history of DM, family history of hypertension, history of gestational diabetes, and physical activity level were analyzed using descriptive statistics. Chi-square tests were used to determine which factors significantly correlated with a diagnosis of diabetes, using the 20% of patients surveyed with known DM. A two-sample t test assuming unequal variances was utilized to determine whether BMI was significantly associated with a diagnosis of DM. The nine symptom-based questions were analyzed using chisquare tests to determine which symptoms significantly correlated with a history of DM (P < 0.05).
Results

Patient Demographics
A total of 305 patients were interviewed and asked to participate in this anonymous and voluntary quality improvement project. Five patients declined to participate in the project. In the pool of 300 enrolled patients, 109 patients were male (37%) and 191 were female (64%) ( Table 2 ). The average age of enrolled patients was 52.0 6 13.3 years, and the average BMI was 31.6 6 7.2 kg/m 2 . Twenty percent of respondents (60 patients) had preexisting DM. One hundred fifty-six patients had a family history of DM (52%), and 16 women had a history of gestational diabetes (8.4%). Additionally, 151 of the 300 patients carried a diagnosis of hypertension (50.3%). When asked about the primary source of their pain, the most frequent response was back pain (49%), followed by joint pain (14%), neck pain (7.7%), radiculopathy (6%), other nerve pain (6%), and headache (6%) ( Table 3) .
Patient demographics (gender, age, BMI, family history of DM, family history of hypertension, history of gestational diabetes, and physical activeness) were analyzed to determine if factors significantly correlated with a risk of diabetes. These results are listed in Table 4 . No significant difference among screening scores was found between the age groups on the ADAQ (P ¼ 0.50) or the SQ (P ¼ 0.40). One-way analysis of variance tests were utilized to compare the scoring of each group.
Diabetes Mellitus Screening
Sixty-five percent of all patients (195 patients) screened positive on the ADAQ, 52 of whom already carried a preexisting of DM. Of note, the ADAQ was negative for eight of the known diabetics. The ADAQ identified 133 patients who carried no diagnosis of DM as being at high risk for undiagnosed DM. Similarly, 61.3% of patients (184 patients) screened positive on the SQ, and 143 patients who do not carry a diagnosis of DM were identified as being at high risk for undiagnosed DM. Hence, the SQ identified an additional 10 patients at risk for undiagnosed DM who were not identified by the ADAQ. These nine questions targeted signs and ), and repeated skin, gum, or bladder infections (P ¼ 1.5 Â 10 À5 ) ( Table 5 ).
In an effort to have the SQ retain a similar sensitivity to the ADAQ, the cutoff threshold for a positive screen was increased from five positive responses (as in the ADA-validated screen) to eight positive responses for the full SQ. Thus, the two questionnaires identified patients at high risk of having undiagnosed or poorly controlled diabetes with comparable sensitivity (86.7% compared with 85%). Due to the addition of the symptom-based questions, the SQ achieved a higher specificity (44.6% compared with 40.4%), and thus an improved PPV nominally (27.7% compared with 26.7%).
Discussion
The project was initiated to identify prevalence of risk and to determine if a routine screening policy for possible DM should be undertaken for patients with a pain diagnosis that could include a corticosteroid injection as part of the treatment plan. Prior to initiation of the project, we had defined 10% prevalence as significant, and the level at which a change in clinic policy would be triggered. This project identified a significant prevalence (65%) in the target patient population as being at high risk of having undiagnosed or inadequately managed DM. While 20% of the patients had known DM, an additional 48% of the cohort were identified as high risk using the screening questionnaire. Unfortunately, because this was a QI project, by our IRB definition, we could not perform laboratory and blood analysis. The ADAQ, however, has been previously validated. By including the nine symptom-based questions, we hoped to increase the specificity and positive specific value of the validated questionnaire. While the SQ identified 10 more patients as at risk than the ADAQ alone, the clinical significance of this cannot be defined without laboratory testing. Future analysis comparing the SQ items with laboratory results is needed to further evaluate the utility of, particularly, the five symptoms that correlated significantly with a positive SQ and to potentially develop a briefer, more efficient questionnaire.
The risk of insulin resistance and hyperglycemia after exposure to corticosteroids is well documented but likely underappreciated by many physicians providing steroid-related interventions for pain. The positive screening rate of 65% strongly supports the need to screen patients for the risk of undertreated hyperglycemia prior to administration of corticosteroids. Yet existing data are inadequate to determine the most efficient and cost-effective method for screening. Clearly the cost of a questionnaire is nominal. On the other hand, the current charge at our institution for point-of-care (POC) glucose is $44, for serum glucose it is $59, and for Hgb A1C it is $145. There is the additional time and inconvenience associated with collecting and processing the sample and incorporating the results into the treatment plan at a time distant from the actual clinic or procedure visit. Thus, universal laboratory screening of all patients could create a significant inconvenience and financial burden for patients and the system. Validation of this screening method with actual laboratory results would help identify thresholds for laboratory testing; actual lab results would also allow for analysis of the SQ to determine if sensitivity could be preserved with some items eliminated. At a minimum, the validated ADAQ should be considered to screen all patients who are being considered for a steroid exposure. If the screen is 
Limitations
This quality improvement project was the initial step in developing a diabetes mellitus screening protocol for the University of Virginia Pain Management Center. The sample size was limited. In addition, because this was done as a QI project, per our IRB definition, patients only completed the screening questionnaires, and no blood tests could be collected. Therefore, it was not possible to directly validate the study questionnaire through obtaining fasting blood glucose or HbA1C.
While a number of patients had a recent serum glucose and/or HbA1C in the electronic medical record, and a smaller number could report their most recent glucose and/or HbA1C, these numbers could not be validated and the overall number was insufficient to perform any statistical analysis. The relatively small size of the cohort may also have impacted the significance of the signs and symptoms on identification of patients at risk for DM. While they did identify 10 patients who were not identified by the ADAQ, it is impossible to determine the validity or significance of this without laboratory results to deny or confirm the presence of hyperglycemia. The SQ needs further validation by comparing the results to glucose and Hgb A1C levels.
Conclusion
The high prevalence of positive screening for the risk of undiagnosed or poorly controlled DM (65%) using the SQ in the study population was unexpected and very concerning. These results suggest that greater attention should be paid to screening patients for DM prior to corticosteroid exposure. The initial screening of these patients may be readily accomplished through use of a questionnaire administered during the clinic visit prior to procedure scheduling. Positive risk scores should prompt diagnostic testing for DM. Steroids should be avoided in patients with markedly abnormal HbA1c levels until patients have achieved better glycemic control due to the risk of significant hyperglycemia and its attendant morbidity and mortality. Finally, patients with DM should be educated regarding the risks associated with corticosteroid injections and the need to report signs and symptoms consistent with hyperglycemia
